Crossmark

Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12885-020-07143-2

Published Online: 2020-07-13

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Changjun

Lin, Yan

Zhou, Yidong

Mao, Feng

Zhu, Hanjiang

Guan, Jinghong

Zhang, Xiaohui

Shen, Songjie

Huang, Xin

Chen, Chang

Yao, Ru

Zhao, Jialin

Sun, Qiang https://orcid.org/0000-0002-6235-0298
Funding

Funding for this research was provided by:

JiangSu HengRui Medicine (NA)
License Information

Text and Data Mining valid from 2020-07-13

Version of Record valid from 2020-07-13
More Information

Article History

Received: 5 September 2019

Accepted: 7 July 2020

First Online: 13 July 2020

Ethics approval and consent to participate

: The study proposal and study materials were approved by the IRB/IEC of Peking Union Medical College Hospital (PUMCH), (ID: HS-2029). All participants provided written informed consent to participate and are free to withdraw at any time.

: Not applicable.

: The authors report no conflicts of interest in this work.

Document is current

Any future updates will be listed below